Interventional Glaucoma

The research points to the importance of isolating offending organism.

According to Sarah Van Tassel, MD, physicians may need to recognize issues and treat patients more holistically.

APOE4 gene associated with Alzheimer’s disease risk was found to protect mice from glaucoma. Research team also prevented retinal ganglion cell death by blocking the APOE signaling pathway, pointing to a potential treatment strategy for glaucoma.

A team of investigators has found that myopic refractive error is linked with an increased risk of primary open-angle glaucoma, and they indicate that the connection has a genetic foundation.

According to the company, a study shows the non-implantable minimally invasive glaucoma surgery effectively reduces IOP and reduces need for IOP-lowering medications in patients diagnosed with open-angle glaucoma.

According to a new study from New York Eye and Ear Infirmary of Mount Sinai, a new, non-invasive ocular imaging method may be able to detect an early indicator of glaucoma in time to prevent disease progression and vision loss.

Flavoprotein fluorescence could serve as a new biomarker, according to a Mount Sinai study.

The doctors will join the Cataract and Primary Eye Care, Glaucoma, and Retina Services.

Mount Sinai study could lead to earlier and increased screening for this population to prevent blindness.

Janet B. Serle, MD, discusses the pros and cons of various treatment options.

A novel eye drop under development may provide neuroprotection to the retinal ganglion cells.

Researchers at the University of Strathclyde have developed an affordable device which takes 3D images and could shift the landscape of eye screening and treatment around the world.

The program — entitled “Pumping Adrenaline!” — brings viewers myriad challenging cases, intraoperative complications, and complex problems following cataract surgery.

The University of Oklahoma Health Sciences Center has received an unrestricted grant from Research to Prevent Blindness for $575,000 over 5 years to support eye research conducted by the Department of Ophthalmology.

Ehsan Sadri, MD FACS, A minimally invasive glaucoma surgery specialist discusses impressions and key take away points from patient case.

Ehsan Sadri, MD FACS reviews the case of a 67-year-old white female with open angle glaucoma and how she benefits from minimally invasive glaucoma surgery.

A minimally invasive glaucoma surgery specialist discusses impressions and key take away points from patient case and how minimally invasive glaucoma surgery has changed the landscape of open angle glaucoma.

Ehsan Sadri, MD, FACS, reviews the case of a 58-year-old male with open angle glaucoma utilizing minimally invasive glaucoma surgery procedure.

The research from eye care nonprofit Orbis International focuses on diabetic retinopathy in Rwanda, where associated vision complications from diabetes are growing.

Automated 360-degree goniophotography seems to have simplified screening and diagnosis of glaucoma.

Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.

Investigators find the recognition could improve surveillance of the disease.

The 10-week Flying Eye Hospital program will offer courses focusing on advanced glaucoma and simulation lectures for residents.

Two year data shows a promising future for the OCD guided, noninvasive technology for glaucoma treatment.

Bath was recognized as the first Black woman physician to receive a medical patent, as well as the first woman to lead a post-graduate training program in ophthalmology. She joins four other inventors as the most recent inductees into the Hall.

Michelle Senchyna, PhD, VP Clinical Development and Medical Affairs for Aerie Pharmaceuticals, gives a company update on the various clinical trials in the pipeline.

Joseph Panarelli, MD, and Arsham Sheybani, MD, discuss the Primary Trabeculectomy for Advanced Glaucoma: Pragmatic Multicentre Randomized Controlled Trial, or TAGS trial, and how this can apply to real world situation. This multicenter randomized controlled trial evaluated whether primary trabeculectomy or primary medical treatment leads to improved outcomes in terms of quality of life, clinical effectiveness, and safety.

Investigators from the New York University Grossman School of Medicine presented data at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver that concluded mapping of the relative cerebrovascular reactivity in the murine brain showed widespread brain changes resulting from the chronic IOP elevation, and demonstrates vascular involvement in glaucoma both within and beyond the primary visual pathways.

Riad Sherif, MD, CEO of Oculis, gives a company update on clinical trials for products in DME, ocular surgery, and more; plus, growing products in glaucoma treatments, team and financing updates.